Proinflammatory cytokines and receptor activator of nuclear factor κB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn's disease

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 2, 2009, Pages 159-166

  Turk, Niksa ^a,d   Cukovic Cavka, Silvija ^a   Korsic, Mirko ^b   Turk, Zdenka ^c   Vucelic, Boris ^a  

^a Department of Gastroenterology ^*  (Croatia)

^b KBC Zagreb   (Croatia)

^c University of Zagreb   (Croatia)

^d UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Crohn's disease; Metabolic bone disease; Osteoprotegerin; Proinflammatory cytokines; Receptor activator of nuclear factor B ligand

Indexed keywords

BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CORTICOSTEROID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; AUTACOID; BIOLOGICAL MARKER; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; CYTOKINE; GLUCOCORTICOID; OSTEOCALCIN; PEPTIDE; PEPTIDE FRAGMENT; PROCOLLAGEN;

ADULT; ARTICLE; BONE DEFECT; BONE DENSITY; CONTROLLED STUDY; CROHN DISEASE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; SCORING SYSTEM; ADOLESCENT; BLOOD; BONE DISEASES, METABOLIC; BONE REMODELING; COMPLICATION; FRACTURES, BONE; PATHOPHYSIOLOGY; PHYSIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES, METABOLIC; BONE REMODELING; COLLAGEN TYPE I; CROHN DISEASE; CYTOKINES; FEMALE; FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; INFLAMMATION MEDIATORS; MALE; OSTEOCALCIN; OSTEOPOROSIS; OSTEOPROTEGERIN; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; RANK LIGAND; YOUNG ADULT;

EID: 59149086356     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283200032     Document Type: Article

References (33)

1. Tilg H. Role of cytokines and their receptors in inflammatory bowel diseases.In: Colombel JF, Gasche C, Scholmerich J, Vucelić B, editors. Inflammatory bowel disease: translation from basic research to clinical practice. Falk Symposium 140. Heidelberg: Springer-Verlag; 2005. pp. 83-89.
2. Bamias G, Nyce MR, De La Rue SA, Cominelli F. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med 2005; 143:895-904.
3. Kethu SR. Extraintestinal manifestations of inflammatory bowel diseases. J Clin Gastroenterol 2006; 40:467-475.
4. Bernstein CN, Leslie WD, Leboff MS. American gastroenterological association technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:795-841.
5. Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut 2004; 53:251-255.
6. Stockbrugger RW, Schoon EJ, Bolani S, Mills PR, Israeli E, Landgraf L, et al.; on behalf of the MATRIX study group. Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease. Aliment Pharmacol Ther 2002; 16:1519-1527.
7. Siffledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, et al. Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease. Inflamm Bowel Dis 2004; 10:220-228.
8. Hofbauer LC, Heufelder AE The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 2000; 85:2355-2363.
9. Kong YY, Boyle WJ, Penninger JM. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today 2000; 21:495-502.
10. Kong YY, Penninger JM. Molecular control of bone remodeling and osteoporosis. Exp Gerontol 2000; 35:947-956.
11. Weitzmann MN, Pacifici R. The role of T lymphocytes in bone metabolism. Immunol Rev 2005; 208:154-168.
12. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007; 7:292-304.
13. Turk N, Kastelan D, Cukovic-Cavka S, Kraljevic I, Korsic M, Vucelic B. Discriminatory ability of calcaneal quantitative ultrasound in the assessmert of bone status in patients with inflammatory bowel disease. Ultrasound Med Biol 2007; 33:863-869.
14. Schoon EJ, Geerling BG, Van Dooren IMA, Schurgers LJ, Vermeer C, Brummer RJM, Stockbrugger RW. Abnormal bone turnover in long-standing Crohn's disease in remission. Aliment Pharmacol Ther 2001; 15:783-792.
15. Schoon EJ, Blok BM, Geerling BJ, Russell MG, Stockbrugger RW, Brummer RJM. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 2000; 119:1203-1208.
16. Lee SH, Kim HJ, Yang SK, Kim WH, Joo YS, Dong SH, et al. Decreased trabecular bone mineral density in newly diagnosed inflammatory bowel disease patients in Korea. J Gastroenterol Hepatol 2000; 15:512-518.
17. Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005; 54:479-487.
18. Franchimont N, Reenaers C, Lambert C, Belaiche J, Bours V, Malaise M, et al. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clin Exp Immunol 2004; 138:491-498.
19. Bernstein CN, Sargent M, Leslie WD. Serum osteoprotegerin is increased ir Crohn's disease: a population-based case control study. Inflamm Bowel Dis 2005; 11:325-330.
20. Byrne FR, Morony S, Warmington K, Geng Z, Brown HL, Flores SA, et al. D4( + )CD45RB(Hi) T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut 2005; 54:78-86.
21. Roggia C, Gao YH, Cenci S, Weitzmann MN, Toraldo G, Isaia G, et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 2001; 98:13960-13965.
22. Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 2001; 276:563-568.
23. Westermann J, Engelhardt B, Hoffmann JC. Migration of T cells in vivo: molecular mechanisms and clinical implications. Ann Intern Med 2001; 135:279-295.
24. Gordon CM. Bone loss in children with Crohn disease: evidence of 'osteoimmune' alterations. J Pediatr 2006; 148:429-432.
25. Sylvester FA, Davis PM, Wyzga N, Hyams JS, Lerer T. Are activated T cells regulators of bone metabolism in children with Crohn disease? J Pediatr 2006; 148:461-466.
26. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol 2005; 100:2031-2035.
27. Ryan BM, Russel MG, Schurgers L, Wichers M, Sijbrandij J, Stockbrugger RW, Schoon E. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study. Aliment Pharmacol Ther 2004; 20:851-857.
28. Franchimont N, Putzeys V, Collette J, Vermeire S, Rutgeerts P, De Vos M, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther 2004; 20:607-614.
29. Gengenbacher M, Sebald HJ, Vllliger PM, Hofstetter W, Seitz M. Infliximab inhibits bone resorption by circulating osteoclast precursor cell in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2008; 67:620-624.
30. Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998; 93:1483-1490.
31. Sylvester FA, Wyzga N, Hyams JS, Gronowicz GA. Effect of Crohn's disease on bone metabolism in vitro: a role for interleukin-6. J Bone Miner Res 2002; 17:695-702.
32. Franchimont N, Wertz S, Malaise M. Interleukin-6: an osteotropic factor influencing bone formation? Bone 2005; 37:601-606.
33. Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Porro GB. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J Intern Med 2000; 247:63-70.